Last reviewed · How we verify
Simulant agent for Zhi Kang Capsule
Zhi Kang Capsule is a marketed simulant agent developed by Peking University People's Hospital, with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its current market presence and the protection of its key patent until 2028. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Simulant agent for Zhi Kang Capsule |
|---|---|
| Sponsor | Peking University People's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: